NCT02227251Phase 2Terminated

Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)

Study sponsor: Karyopharm Therapeutics Inc · KPTI

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2026-06-02Actual
Enrollment · participants279Actual
Source updated2026-11-19Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 5 fields changed

Participant count type changed

Before: Estimated. After: Actual.

Enrollment · participant count changed

Before: 244 participants (planned). After: 279 participants (actual).

Completion date type changed

Before: Estimated. After: Actual.

Primary completion date changed

Before: Dec 2026. After: 2 Jun 2026.

Recruitment status changed

Before: Active not recruiting. After: Terminated.

Check registry source

· 2 fields changed

Primary completion date changed

Before: Apr 2027. After: Dec 2026.

Recruitment status changed

Before: Recruiting. After: Active not recruiting.

Check registry source